Peter Attia· MD
Randy with colleagues of his worked out a way to encapsulate the Romy in a capsule plastic capsule that makes it through the stomach and dissolves in the more alkaline conditions of the small intestine
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Randy with colleagues of his worked out a way to encapsulate the Romy in a capsule plastic capsule that makes it through the stomach and dissolves in the more alkaline conditions of the small intestine
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
the famous One the early one was rap ayin about 90% of the Romy that was given to mice in the food never made it into the mouse because it's digested in the stomach and the acid conditions of the stomach it gets degraded
Randy with colleagues of his uh worked out a way to encapsulate the Romy in a capsule plastic capsule that makes it through the stomach and dissolves in the more alkaline conditions of the small intestine so that was a way of tricking the body into getting the ramiz into the portion of of the GI tract where it could be absorbed
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.